apararenone apararenone apararenone (inn) (developmental code name mt-3995) is a nonsteroidal antimineralocorticoid which is under development by mitsubishi tanabe pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. it was also previously being developed for the treatment of hypertension, but development was discontinued for this indication. apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (ki < 50 nm), the receptor for aldosterone. as of 2017, it is in phase ii clinical trials. apararenoneclinical dataother namesmt-3995routes ofadministrationoraldrug classantimineralocorticoididentifiers iupac name n-methanesulfonamide cas number945966-46-1pubchem cid24744336chemspider28663572unii832663u2nbchemblchembl2181929chemical and physical dataformulac17h17fn2o4smolar mass364.39 g·mol−13d model (jsmol)interactive image smiles cc1(c(=o)n(c2=c(o1)c=c(c=c2)ns(=o)(=o)c)c3=cc=c(c=c3)f)c inchi inchi=1s/c17h17fn2o4s/c1-17(2)16(21)20(13-7-4-11(18)5-8-13)14-9-6-12(10-15(14)24-17)19-25(3,22)23/h4-10,19h,1-3h3key:aznhwxafpbyfgh-uhfffaoysa-n